Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.
Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy. The data obtained suggest the presence of acquired maturation abnormalities in the B cell compartment.
D000361:Agammaglobulinemia / Q000139:chemically induced*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001402:B-Lymphocytes / Q000187:drug effects*; D004112:Dimercaprol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008667:Metalloproteins / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D050607:Organogold Compounds; D009942:Organometallic Compounds; D020005:Propanols; D013256:Steroids; D013438:Sulfhydryl Compounds
D000893:Anti-Inflammatory Agents; D008667:Metalloproteins; D050607:Organogold Compounds; D009942:Organometallic Compounds; D020005:Propanols; D013256:Steroids; D013438:Sulfhydryl Compounds; D004112:Dimercaprol; C013394:aurotioprol